Abstract
Background
Low-grade glioma (LGG) is a common central nervous system tumor with high recurrence rates and limited long-term survival improvements despite current treatments. Anoikis, a form of programmed cell death triggered by detachment from the extracellular matrix, plays a key role in tumor progression and metastasis. However, its involvement in LGG remains poorly understood.
Objective
This study aims to analyze the molecular features, subgrouping, and clinical prognostic significance of disruption-induced anoikis in low-grade glioma using bioinformatics analysis and experimental validation.
Methods
We integrated transcriptome and clinical information data from the TCGA and CGGA databases. We identified prognosis-related genes associated with disruption-induced anoikis and glioma through analysis of the anoikis gene set. Survival prognosis analysis was performed on these genes. Furthermore, dimensional reduction clustering and enriched analysis of GO/KEGG were conducted to explore the biological functions and signal pathways of disruption-induced anoikis genes in glioma. Drug sensitivity screening and immune-related function analysis were also carried out.
Results
Our bioinformatics analysis identified 266 anoikis genes, including BRMS1, NTRK2, CAV1, AKT1, and ITGB1, which significantly influenced overall survival in low-grade glioma patients. Clustering analysis revealed three distinct clusters, with cluster C having the worst prognosis. The anoikis genes were associated with metabolic pathways, immune cells, and cell cycle-related pathways. Enriched analysis showed immune-related functions and signaling pathways. Drug sensitivity screening identified potential drugs with clinical efficacy, such as cisplatin, doxorubicin, erlotinib, and etoposide. A prognostic model was constructed for anoikis-related genes, showing significant survival differences. Immune checkpoint analysis indicated sensitivity to immunotherapy. Experimental validation confirmed the downregulation of prognosis-related risk genes for anoikis in human glioma cell lines, inhibiting cell anoikis.
Conclusion
This study provides insights into the molecular characteristics and clinical importance of disruption-induced anoikis in low-grade glioma. The findings contribute to the understanding of glioma progression and offer potential therapeutic targets.
Get full access to this article
View all access options for this article.
References
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
